

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO. CONFIRMATION NO.		
10/583,285	06/16/2006	Henri Delalu	047578/312784	2640	
826 ALSTON & B	7590 10/31/200 SIRD LLP	7	EXAMINER		
BANK OF AMERICA PLAZA			DAVIS, BRIAN J		
	TRYON STREET, SUIT E, NC 28280-4000	E 4000	ART UNIT PAPER NUMBER		
			1621		
			MAIL DATE	DELIVERY MODE	
			10/31/2007	PAPER	

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No.	Applicant(s)	
Office Action Summers	10/583,285	DELALU ET AL.	
Office Action Summary	Examiner	Art Unit	
	Brian J. Davis	1621	
The MAILING DATE of this communication Period for Reply	n appears on the cover sheet wit	h the correspondence address	
A SHORTENED STATUTORY PERIOD FOR R WHICHEVER IS LONGER, FROM THE MAILIN - Extensions of time may be available under the provisions of 37 C after SIX (6) MONTHS from the mailing date of this communicative. If NO period for reply is specified above, the maximum statutory period for reply within the set or extended period for reply will, by Any reply received by the Office later than three months after the earned patent term adjustment. See 37 CFR 1.704(b).	IG DATE OF THIS COMMUNIC FR 1.136(a). In no event, however, may a report. Deriod will apply and will expire SIX (6) MONT statute, cause the application to become ABA	ATION. ply be timely filed HS from the mailing date of this communication INDONED (35 U.S.C. § 133)	
Status			
1) Responsive to communication(s) filed on			
·	This action is non-final.		
3) Since this application is in condition for al		re prosecution as to the merits is	ı
closed in accordance with the practice un		·	1
Disposition of Claims	an expans queyro, 1000 c.b.		
4)⊠ Claim(s) <u>13-28</u> is/are pending in the appli	cation		
4a) Of the above claim(s) is/are with			
5) Claim(s) is/are allowed.	na awn nom oonsideration.		
6)⊠ Claim(s) <u>28</u> is/are rejected.			
7)⊠ Claim(s) <u>13-27</u> is/are objected to.			
8) Claim(s) are subject to restriction a	ind/or election requirement.		
Application Papers	·		
· _			
 9)⊠ The specification is objected to by the Exa 10)⊠ The drawing(s) filed on 16 June 2006 is/ar 		had to but the Francisco	
Applicant may not request that any objection to	· · · · ·	•	
Replacement drawing sheet(s) including the co			١
11) ☐ The oath or declaration is objected to by the		· · · · · · · · · · · · · · · · · · ·).
Priority under 35 U.S.C. § 119			
12)⊠ Acknowledgment is made of a claim for for a)⊠ All b)□ Some * c)□ None of:	reign priority under 35 U.S.C. §	119(a)-(d) or (f).	
1. Certified copies of the priority docur	ments have been received.		
2. Certified copies of the priority docur		plication No	
3. Copies of the certified copies of the	priority documents have been r	eceived in this National Stage	
application from the International Bu	ıreau (PCT Rule 17.2(a)).		
* See the attached detailed Office action for a	a list of the certified copies not re	eceived.	
Attachment(s)		· ·	
1) ⊠ Notice of References Cited (PTO-892) 2) ☑ Notice of Draftsperson's Patent Drawing Review (PTO-948	4) LInterview Su Paper No(s)	mmary (PTO-413) Mail Date	
3) Information Disclosure Statement(s) (PTO/SB/08)	5) D Notice of Inf	ormal Patent Application	
Paper No(s)/Mail Date <u>6/16/06;5/17/07</u> .	6) 🔛 Other:		

Application/Control Number: 10/583,285

Art Unit: 1621

DETAILED ACTION

Specification

The disclosure is objected to because:

This application does not contain an abstract of the disclosure as required by 37 CFR 1.72(b). An abstract on a separate sheet is required.

The specification does not contain a Brief Description of the Drawings section. See MPEP 608.01(f). Appropriate correction is required.

The specification on page 9, line 26, contains an obvious error *viz*. the term allylhydrazine should be deleted and replaced with allylamine.

Allylhydrazine is the product of the reaction, not a starting material. Appropriate correction is required.

Applicant's assistance is respectfully requested in correcting any other minor errors which may be present in the specification.

Claim Objections

Claim 13 is objected to because of the following informalities: in step (b) of the claim, the term "step a" should instead be "step (a)" in order to maintain a consistent terminology throughout the text. Appropriate correction is required.

Claim 21 is objected to because of the following informalities: the first instance of the term "step (a)" should instead be "step (c)." This appears to be a typographical error. Appropriate correction is required.

Application/Control Number: 10/583,285

Art Unit: 1621

Applicant's assistance is respectfully requested in correcting any other minor errors which may be present in the claims.

Claim Rejections - 35 USC § 112

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claim 28 is rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. The term "approximately" is a relative term which renders the claim indefinite. The term is not defined by the claim, the specification does not provide a standard for ascertaining the requisite degree, and one of ordinary skill in the art would not be reasonably apprised of the scope of the invention.

Allowable Subject Matter

Claims 14-27 are objected to as being dependent upon a base claim which has been objected to, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims. The following is a statement of reasons for the indication of allowable subject matter:

The closet prior art appears to be *Journal of the American Chemical Society*, 1955, Vol. 77, p. 3131, cited by applicant in the IDS, which teaches the synthesis of allylhydrazine from allylamine and chloramine (experimental

Application/Control Number: 10/583,285

Art Unit: 1621

section). The procedure followed is described to be similar to that detailed in *Journal of the American Chemical Society*, 1954, Vol. 76, p. 4869-4871 (page 4871, first full paragraph) for the synthesis of alkylhydrazines.

The cited prior art neither teaches nor suggests the instant process. Nor would it have been obvious to one of ordinary skill in the art at the time of the invention to modify the teachings of the prior art in order to arrive at those of the instant invention. There is no motivation to do so.

Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Brian J. Davis whose telephone number is 571-272-0638. The examiner can normally be reached on M-F 8:30-5:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Yvonne (Bonnie) Eyler can be reached at 571-272-0871. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Art Unit: 1621

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Brian J. Davis

October 24, 2007